We have isolated, cloned, and characterized multiple T cell receptors (TCRs) from human donors specific for common mutations in KRAS and restricted to highly prevalent HLA types. These TCRs, protected by a Penn provisional filing, are suitable for T cell engineering for the adoptive immunotherapy of cancer patients of select HLA types and tumors expressing particular KRAS mutantions.
The comprehensive bioinformatics, biochemical and immunological assessment of these TCRs is in press (Bear et al, Nature Communications).
Published: 10/16/2023